KRAS and colorectal carcinoma: KRAS mutations were historically considered “undruggable”.13 The discovery of the cysteine pocket enabled the development of selective KRASG12C inhibitors.14,15 Patients with CRC harbouring KRASG12C mutations often have worse survival outcomes.